Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.63 |
| ▸ | FFAR1 | O14842 | 10/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL709052 | 0.89 | HDAC3 (0.66) | KEAP1FFAR1HDAC3MAPK1ADRA1A | |
| SCHEMBL711487 | 0.89 | HDAC3 (0.66) | KEAP1FFAR1HDAC3MAPK1ADRA1A | |
| SCHEMBL3589930 | 0.86 | FFAR1 (0.75) | FFAR1TDP1FFAR4 | |
| SCHEMBL7843032 | 0.85 | MAPT (0.68) | KEAP1FFAR1HDAC3MAPK1ADRA1A | |
| SCHEMBL1007091 | 0.85 | MAPT (0.68) | KEAP1FFAR1HDAC3MAPK1ADRA1A | |
| SCHEMBL3594705 | 0.85 | TDP1 (0.52) | KEAP1FFAR1HDAC3MAPK1ADRA1A | |
| SCHEMBL3820690 | 0.85 | TDP1 (0.52) | KEAP1FFAR1HDAC3MAPK1ADRA1A | |
| Acetone SCHEMBL27310709 | 0.83 | ALDH1A1 (0.57) | KEAP1FFAR1MAPK1SMN1; SMN2TDP1 | |
| SCHEMBL13886150 | 0.83 | L3MBTL1 (0.56) | FFAR1TDP1FFAR4ALDH1A1 | |
| SCHEMBL19294596 | 0.83 | FFAR1 (0.55) | KEAP1FFAR1MAPTRXFP1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3650464-B1 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND | SHANGPHARMA INNOVATION INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250099404-A1 | TRANS-4-HYDROXYCYCLOHEXYL PHENYL AMIDE MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | MITOCHONDRIA IN MOTION, INC. (US) | 2025-03-27 | — | — | US | disclosed |
| CN-116813705-A | Peptide compound, application thereof and composition containing peptide compound | 凯惠科技发展(上海)有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-109206481-B | Peptide compound, application thereof and composition containing peptide compound | 尚华医药科技(江西)有限公司 | 2023-08-18 | — | — | CN | disclosed |
| US-11427615-B2 | Peptide compound and application thereof, and composition containing peptide compound | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2022-08-30 | — | — | US | disclosed |
| US-20210251925-A1 | TRANS-4-HYDROXYCYCLOHEXYL PHENYL AMIDE MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | MITOCHONDRIA EMOTION, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-11083699-B2 | Trans-4-hydroxycyclohexyl phenyl amide mitofusin activators and methods of use thereof | MITOCHONDRIA EMOTION, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20200345668-A1 | TRANS-4-HYDROXYCYCLOHEXYL PHENYL AMIDE MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | MITOCHONDRIA EMOTION, INC. (US) | 2020-11-05 | — | — | US | disclosed |
| EP-2869389-B1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION CELL USING SAME | MITSUBISHI CHEM CORP (JP) | 2019-11-13 | — | — | EP | disclosed |
| US-10320030-B2 | Nonaqueous electrolyte solution and nonaqueous electrolyte battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-06-11 | — | — | US | disclosed |
| WO-2007102771-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2007-09-13 | — | — | WO | disclosed |
| US-7229987-B2 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | ELI LILLY AND COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| WO-2007027133-A1 | 7-(2-AMINO-1-HYDROXY-ETHYL)-4-HYDROXYBENZOTHIAZOL-2(3H)-ONE-DERIVATIVES AS β2 ADRENOCEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007018461-A1 | NOVEL BENZOTHIAZOLONE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | AMMENN ET AL, JOCHEN | 2005-12-08 | — | — | US | disclosed |
| EP-1505968-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003097047-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2003-11-27 | — | — | WO | disclosed |
| US-5763465-A | 7-(2-aminoethyl) benzothiazolones | ASTRA PHARMACEUTICALS LIMITED (GB) | 1998-06-09 | — | — | US | disclosed |
| US-5648370-A | 7-(2-aminoethyl) benzothiazolones | ASTRA PHARMACEUTICALS LIMITED (GB) | 1997-07-15 | — | — | US | disclosed |
| WO-1993023385-A1 | BIOLOGICALLY ACTIVE AMINES | FISONS PLC (GB) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345668-A1 | TRANS-4-HYDROXYCYCLOHEXYL PHENYL AMIDE MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | MFN2, TFB2M, HADHA | KEAP1 1310/4885FFAR1 1192/4885HDAC3 2953/4885 |
| US-11427615-B2 | Peptide compound and application thereof, and composition containing peptide compound | KISS1R, VIP, NPY1R | KEAP1 4144/4885FFAR1 342/4885HDAC3 2986/4885 |
| US-11083699-B2 | Trans-4-hydroxycyclohexyl phenyl amide mitofusin activators and methods of use thereof | MFN2, TFB2M, HADHA | KEAP1 1310/4885FFAR1 1192/4885HDAC3 2953/4885 |
| US-20210251925-A1 | TRANS-4-HYDROXYCYCLOHEXYL PHENYL AMIDE MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | MFN2, TFB2M, HADHA | KEAP1 1310/4885FFAR1 1192/4885HDAC3 2953/4885 |
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | MC1R, MC4R, MC5R | KEAP1 1194/4885FFAR1 481/4885HDAC3 1425/4885 |
| US-20250099404-A1 | TRANS-4-HYDROXYCYCLOHEXYL PHENYL AMIDE MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF | MFN2, TFB2M, HADHA | KEAP1 1310/4885FFAR1 1192/4885HDAC3 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.